To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Dynamics of cytotoxic T c… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia

Journal article
Authors Frida Ewald Sander
Anna Rydström
Elin Bernson
Roberta Kiffin
Rebecca E Riise
Johan Aurelius
H. Anderson
Mats Brune
R. Foa
Kristoffer Hellstrand
Fredrik Bergh Thorén
Anna Martner
Published in Oncotarget
Volume 7
Issue 7
Pages 7586-7596
ISSN 1949-2553
Publication year 2016
Published at Sahlgrenska Cancer Center
Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Pages 7586-7596
Language en
Links dx.doi.org/10.18632/oncotarget.7210
Keywords acute myeloid leukemia, immunotherapy, cytotoxic T cells, antigen-specific T cells, Immunology and, histamine dihydrochloride, transplantation, memory, differentiation, interleukin-2, lymphocytes, maintenance, remission, responses, effector, Oncology, Cell Biology
Subject categories Clinical Medicine

Abstract

Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (ClinicalTrials.gov; NCT01347996). Blood samples were drawn during cycles of immunotherapy and analyzed for CD8(+) (cytotoxic) T cell phenotypes in blood. During the first cycle of therapy, a re-distribution of cytotoxic T cells was observed comprising a reduction of T effector memory cells and a concomitant increase of T effector cells. The dynamics of T cell subtypes during immunotherapy prognosticated relapse and survival, in particular among older patients and remained significantly predictive of clinical outcome after correction for potential confounders. Presence of CD8(+) T cells with specificity for leukemia-associated antigens identified patients with low relapse risk. Our results point to novel aspects of T cell-mediated immunosurveillance in AML and provide conceivable biomarkers in relapse-preventive immunotherapy.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://www.gu.se/english/research/publication/?publicationId=233422
Utskriftsdatum: 2019-09-15